Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LYRICA

« Back to Dashboard
Lyrica is a drug marketed by Pf Prism Cv and is included in two NDAs. It is available from eight suppliers. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LYRICA is pregabalin. There are twenty-seven drug master file entries for this compound. Eight suppliers are listed for this compound. There are eight tentative approvals for this compound. Additional details are available on the pregabalin profile page.

Summary for Tradename: LYRICA

Suppliers: see list8
2013 Sales:$2,415,254,000

Clinical Trials for: LYRICA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
CAPSULE;ORAL021446-004Dec 30, 2004RXNo6,001,876<disabled>Y<disabled>
Pf Prism Cv
CAPSULE;ORAL021446-005Dec 30, 2004RXNoRE41920<disabled><disabled>
Pf Prism Cv
CAPSULE;ORAL021446-007Dec 30, 2004RXNo6,197,819<disabled>YY<disabled>
Pf Prism Cv
CAPSULE;ORAL021446-001Dec 30, 2004RXNo6,001,876<disabled>Y<disabled>
Pf Prism Cv
CAPSULE;ORAL021446-002Dec 30, 2004RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LYRICA

Drugname Dosage Strength RLD Submissiondate
pregabalinOral Solution20 mg/mLLyrica5/19/2010
pregabalinCapsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mgLyrica12/30/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn